Monday, 16 Sep 2019

You are here

EULAR 2019 Report – Day 2

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. It was a full and lively second day in Madrid with sessions dedicated to Lupus, RA, Sjogren’s, imaging, rare diseases, psoriatic arthritis and spondyloarthritis. Here are a few of the highlights from day 2 EULAR in Madrid. 

  • Riociquat in SSc-ILD: riociquat is approved in the US for pulmonary arterial hypertension and chronic thromboembolic pulmonary HTN and is now applied to 121 patients with early SSc (<18 mos. Symptoms) and limited scleroderma (mRSS 12-20).  This 52 week ended with a downward trend in skin thickness but did not achieve its primary endpoint (p=0.08).  However when they looked at the 20% of patients who had interstitial lung disease, they found significant reductions in FVC. This was encouraging as the drug was well tolerated.  OP0183
  • The Earlier the Better.  A longitudinal study from a Swedish RA registry examine 6559 RA patients enrolled since 1991 and shown that new, DMARD naïve RA patients, have overtime, demonstrated decreasing levels of joint activity (initial SJC, TJC), CRP, ESR, and increasing patient and evaluator global assessments.  Also decreasing was the time from symptom onset to diagnosis of RA.  So if RA is getting milder, it may well be that we are seeing them sooner, with more expedited diagnoses and hopefully earlier DMARD initiation.  THU0073
  • Machine Learning with Psoriatic Arthritis.  Dr. Ian McInnes presented a novel and futuristic analysis of PsA patients by applying “machine learning” to the secukinumab PsA trials that included >2,700 patients to identify clusters that may lead to more personalized treatment.  Overall they defined 13 clusters of PsA based on patterns of tender joint (TJ) and swollen joint (SJ) involvement. They plan on doing further study of other psoriatic manifestations such as skin and nail involvement to describe a range of phenotypes that explains PsA variability.  OP0114

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

RheumNow Podcast – The End of Arthritis (9.13.19)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

RheumNow Podcast – Do’s and Don’ts in Spondylitis (9.5.19)

Dr. Jack Cush reviews the news and important research published in the last two weeks on RheumNow.com.

Influenza Vaccination Update

FDA's Vaccines and Related Biological Products Advisory Committee met in Silver Spring, Maryland, on March 6 and 22, 2019, to select the influenza viruses for the composition of the influenza vaccine for the 2019-2020 U.S. influenza season.

RheumNow Podcast - I Wanna New Drug (8-30-19)

Dr. Jack Cush vents on choosing new therapies in rheumatoid arthritis.

RheumNow Podcast – Upadacitinib FDA Approved for RA (8.23.19)

Dr. Jack Cush reports on the news and journal reports from the past week on RheumNow.com, including: how your genetics may shape your microbiome; GERD as a risk factor for TMJ?; how can MDA-5+ dermatomyositis be any worse; new drug happenings; StillsNow.com; and more.